Lower-Risk MDS: A Review of Data from the ASH 2022 Annual Meeting - Episode 2

Luspatercept in Lower-Risk MDS

, , ,

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

EP. 1: First- and Second-Line Treatment Options in Lower-Risk MDS
Now Viewing
EP. 2: Luspatercept in Lower-Risk MDS
EP. 3: Emerging Therapies for Lower-Risk MDS

Data from the following clinical trials are discussed:

  • 3098: Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study
  • 4408: Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study
  • 1774: Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial
  • 389: Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns